Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.3.1925

Association Between MDM2 SNP309 T>G and Risk of Gastric Cancer: A Meta-analysis  

Tian, Xin (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Tian, Ye (Department of Thoracic Surgery, the Fouth Affiliated Hospital of China Medical University)
Ma, Ping (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Sui, Cheng-Guang (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Meng, Fan-Dong (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Li, Yan (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Fu, Li-Ye (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Jiang, Tao (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Wang, Yang (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Ji, Fu-Jian (Department of General Surgery, Second Hospital of Jilin University (Disease Treatment Center of Jilin University General Surgery))
Fang, Xue-Dong (Department of General Surgery, Second Hospital of Jilin University (Disease Treatment Center of Jilin University General Surgery))
Jiang, You-Hong (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.3, 2013 , pp. 1925-1929 More about this Journal
Abstract
Background: As a negative regulator of P53, MDM2 plays an important role in carcinogenesis; a polymorphism in its promoter region. SNP309 T>G, is known to increase the expression of MDM2, thus being considered related to higher susceptibility to neoplasia. However, no agreement has been achieved regarding its effects on gastric cancer. Methods: The present systematic meta-analysis was performed based on comprehensive literature search from Pubmed, Web of science and CBM databases. Results: It was suggested from 6 independent studies that the GG genotype is associated with a significantly increased risk of gastric cancer (Recessive: OR = 1.43, 95% CI = 1.08-1.91, P = 0.013), and subgroup analysis also confirmed the relationship (English publications-recessive model: OR = 1.45, 95% CI = 1.10-1.91, P = 0.009; Studies in China-recessive model: OR = 1.58, 95% CI = 1.08-2.30, P = 0.017). No publication bias was detected. Conclusion: The meta-analysis indicated a significant inverse association between GG genotype carriage and elevated risk of gastric cancer. However, more studies and detailed information are needed to fully address the topic.
Keywords
MDM2; polymorphism; gastric cancer; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.   DOI   ScienceOn
2 Bond GL, Hu W, Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4.   DOI   ScienceOn
3 Cai X, Yang M (2012). The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol, 138, 555-61.   DOI   ScienceOn
4 Chen T, Yi SH, Liu XY, et al (2012). Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev, 13, 4327-30.   과학기술학회마을   DOI   ScienceOn
5 Cho YG, Choi BJ, Song JH, et al (2008). No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 55, 256-60.
6 Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
7 Eischen CM, Lozano G (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell, 15, 161-2.   DOI   ScienceOn
8 Er LM, Niu WW, Xu ZB, et al (2009). Relation of MDM2 gene polymorphism and Helicobacter pylori infection to gastric cardiac carcinoma. Clin Focus, 24, 1594-7.
9 Er LM (2012). Relevance of MDM2 polymorphisms with esophageal squamous cell carcinoma, gastric adenocarcinoma and double primary cancers in esophagus and stomach. Modern Prev Med, 39, 3342-4.
10 Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35.   DOI   ScienceOn
11 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
12 Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907.   DOI   ScienceOn
13 Zhang L, et al (2011). Association of gene polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. Chongqing Medical School.
14 Wang X, Yang J, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9.
15 Yang L (2006). Incidence and mortality of gastric cancer in China. World J Gastroenterol, 12, 17-20.
16 Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001.   DOI   ScienceOn
17 Zhao P, Dai M, Chen W, et al (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5.   DOI   ScienceOn
18 Li YQ, et al (2010). Interaction of Helicobacter pylori with MDM2 SNP309 polymorphisms and susceptibility to gastric cancer studies. Nanjing Medical School.
19 Knappskog S, Bjornslett M, Myklebust LM, et al (2011). The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell, 19, 273-82.   DOI   ScienceOn
20 Knappskog S, Lonning PE (2011). Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2, 207-10.   DOI
21 Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
22 Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6.   과학기술학회마을   DOI   ScienceOn
23 Ohmiya N, Taguchi A, Mabuchi N, et al (2006). MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40.   DOI   ScienceOn
24 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
25 Society AC (2013). Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
26 Stolte M, Meining A (1998) Helicobacter pylori and Gastric Cancer. Oncologist, 3, 124-8.
27 Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7.   DOI